Drug Trial Radar · NCT05852730
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Last checked: Nov 20, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 10, 2021
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Repurposed Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Aeronautics and Space Administration (NASA)
- First posted
- May 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary specific aim of this Field Test aim is to evaluate the feasibility and efficacy of administering the intranasal scopolamine gel in operational field settings using both astronaut and ground-control subjects that are exposed to provocative motion as part of their assigned duties. For the ground-control subjects, these may include motion simulations (e.g., centrifuge), parabolic flights and/or Orion capsule recovery operations. Astronaut participants may choose to test Inscop during provocative preflight training exercises (e.g., centrifugation), and can choose to take the medication prophylactically to prevent symptoms or after symptom onset to treat motion sickness during the launch and/or landing mission phases. Both ground-control and astronaut participants will be required to test the medication during a training session to monitor for adverse side effects. Participants in the field test aim will complete short debrief questionnaires to capture motion sickness symptoms, side effects, and feasibility comments. The investigators will also include field "control" subjects who did not take (INSCOP) to comment on what countermeasures subjects used and their effectiveness. The investigators will be recruiting astronaut participants from free-flier missions (e.g., SpaceX Polaris Dawn), Private Astronaut Missions (e.g., Axiom), and standard missions to the International Space Station.
Conditions
- Motion Sickness, Space
- Motion Simulation
- Parabolic Flight
Interventions
DPI-386 Nasal GelDrug
Subjects will self-administer DPI-386 Nasal Gel
Other (e.g., promethazine, meclizine)Drug
Subjects will self-administer other medications as available.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Motion sickness (MS) symptoms using Pensacola Diagnostic Index (PDI) nausea scale.Time frame: 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NASA Johnson Space Center Neuroscience Laboratory
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.